51
|
Lu H, Sun J, Liang W, Zhang J, Rom O, Garcia-Barrio MT, Li S, Villacorta L, Schopfer FJ, Freeman BA, Chen YE, Fan Y. Novel gene regulatory networks identified in response to nitro-conjugated linoleic acid in human endothelial cells. Physiol Genomics 2019; 51:224-233. [PMID: 31074702 PMCID: PMC6620647 DOI: 10.1152/physiolgenomics.00127.2018] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2019] [Revised: 03/05/2019] [Accepted: 04/24/2019] [Indexed: 12/11/2022] Open
Abstract
Endothelial cell (EC) dysfunction is a crucial initiation event in the development of atherosclerosis and is associated with diabetes mellitus, hypertension, and heart failure. Both digestive and oxidative inflammatory conditions lead to the endogenous formation of nitrated derivatives of unsaturated fatty acids (FAs) upon generation of the proximal nitrating species nitrogen dioxide (·NO2) by nitric oxide (·NO) and nitrite-dependent reactions. Nitro-FAs (NO2-FAs) such as nitro-oleic acid (NO2-OA) and nitro-linoleic acid (NO2-LA) potently inhibit inflammation and oxidative stress, regulate cellular functions, and maintain cardiovascular homeostasis. Recently, conjugated linoleic acid (CLA) was identified as the preferential FA substrate of nitration in vivo. However, the functions of nitro-CLA (NO2-CLA) in ECs remain to be explored. In the present study, a distinct transcriptome regulated by NO2-CLA was revealed in primary human coronary artery endothelial cells (HCAECs) through RNA sequencing. Differential gene expression and pathway enrichment analysis identified numerous regulatory networks including those related to the modulation of inflammation, oxidative stress, cell cycle, and hypoxic responses by NO2-CLA, suggesting a diverse impact of NO2-CLA and other electrophilic nitrated FAs on cellular processes. These findings extend the understanding of the protective actions of NO2-CLA in cardiovascular diseases and provide new insight into the underlying mechanisms that mediate the pleiotropic cellular responses to NO2-CLA.
Collapse
Affiliation(s)
- Haocheng Lu
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center , Ann Arbor, Michigan
| | - Jinjian Sun
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center , Ann Arbor, Michigan
| | - Wenying Liang
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center , Ann Arbor, Michigan
| | - Jifeng Zhang
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center , Ann Arbor, Michigan
| | - Oren Rom
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center , Ann Arbor, Michigan
| | - Minerva T Garcia-Barrio
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center , Ann Arbor, Michigan
| | - Shengdi Li
- Genome Biology Unit, European Molecular Biology Laboratory (EMBL) , Heidelberg , Germany
| | - Luis Villacorta
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center , Ann Arbor, Michigan
| | - Francisco J Schopfer
- Department of Pharmacology and Chemical Biology, University of Pittsburgh , Pittsburgh, Pennsylvania
| | - Bruce A Freeman
- Department of Pharmacology and Chemical Biology, University of Pittsburgh , Pittsburgh, Pennsylvania
| | - Y Eugene Chen
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center , Ann Arbor, Michigan
| | - Yanbo Fan
- Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center , Ann Arbor, Michigan
| |
Collapse
|
52
|
Zatloukalova M, Mojovic M, Pavicevic A, Kabelac M, Freeman BA, Pekarova M, Vacek J. Redox properties and human serum albumin binding of nitro-oleic acid. Redox Biol 2019; 24:101213. [PMID: 31170679 PMCID: PMC6554544 DOI: 10.1016/j.redox.2019.101213] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2019] [Revised: 04/30/2019] [Accepted: 05/01/2019] [Indexed: 12/27/2022] Open
Abstract
Nitro-fatty acids modulate inflammatory and metabolic stress responses, thus displaying potential as new drug candidates. Herein, we evaluate the redox behavior of nitro-oleic acid (NO2-OA) and its ability to bind to the fatty acid transporter human serum albumin (HSA). The nitro group of NO2-OA underwent electrochemical reduction at -0.75 V at pH 7.4 in an aqueous milieu. Based on observations of the R-NO2 reduction process, the stability and reactivity of NO2-OA was measured in comparison to oleic acid (OA) as the negative control. These electrochemically-based results were reinforced by computational quantum mechanical modeling. DFT calculations indicated that both the C9-NO2 and C10-NO2 positional isomers of NO2-OA occurred in two conformers with different internal angles (69° and 110°) between the methyl- and carboxylate termini. Both NO2-OA positional isomers have LUMO energies of around -0.7 eV, affirming the electrophilic properties of fatty acid nitroalkenes. In addition, the binding of NO2-OA and OA with HSA revealed a molar ratio of ~7:1 [NO2-OA]:[HSA]. These binding experiments were performed using both an electrocatalytic approach and electron paramagnetic resonance (EPR) spectroscopy using 16-doxyl stearic acid. Using a Fe(DTCS)2 spin-trap, EPR studies also showed that the release of the nitro moiety of NO2-OA resulted in the formation of nitric oxide radical. Finally, the interaction of NO2-OA with HSA was monitored via Tyr and Trp residue electro-oxidation. The results indicate that not only non-covalent binding but also NO2-OA-HSA adduction mechanisms should be taken into consideration. This study of the redox properties of NO2-OA is applicable to the characterization of other electrophilic mediators of biological and pharmacological relevance.
Collapse
Affiliation(s)
- Martina Zatloukalova
- Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, Olomouc 775 15, Czech Republic
| | - Milos Mojovic
- Faculty of Physical Chemistry, University of Belgrade, Studentski trg 12-16, Belgrade, Serbia
| | - Aleksandra Pavicevic
- Faculty of Physical Chemistry, University of Belgrade, Studentski trg 12-16, Belgrade, Serbia
| | - Martin Kabelac
- Department of Chemistry, Faculty of Science, University of South Bohemia, Branisovska 31, Ceske Budejovice 370 05, Czech Republic
| | - Bruce A Freeman
- Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh PA, 15261, USA
| | - Michaela Pekarova
- The Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, Brno 612 65, Czech Republic
| | - Jan Vacek
- Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, Olomouc 775 15, Czech Republic; The Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, Brno 612 65, Czech Republic.
| |
Collapse
|
53
|
Affiliation(s)
- Dolores Pérez-Sala
- Department of Structural and Chemical Biology, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, 28040 Madrid, Spain.
| | - Rosário Domingues
- Mass Spectrometry Center&QOPNA, Department of Chemistry, Department of Chemistry & CESAM& ECOMARE, University of Aveiro, 3810-193 Aveiro, Portugal
| |
Collapse
|
54
|
Abstract
Fatty acids not only provide caloric energy in our diets and building blocks of lipids but are also precursors of potent signaling molecules. Fatty acids can undergo enzymatic and non-enzymatic transformations to form autocrine and paracrine signaling molecules that regulate energy balance and metabolic homeostasis. A new class of lipid signaling mediators known as nitro-fatty acids (NO2-FAs) has recently been identified. These NO2-FAs are generated endogenously through non-enzymatic reactions of secondary products of nitrite and nitric oxide and are readily detected in human plasma and urine. NO2-FAs are potent anti-inflammatory and antioxidant cell signaling mediators and exert protective effects in numerous pre-clinical animal models of disease including cardiovascular, pulmonary and renal fibrosis. Chronic unresolved inflammation is common key feature underlying most fibrotic disorders. Two pathways that converge on inflammation and oxidative stress are nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and nuclear factor kappa B (NF-κB). NO2-FAs are pleiotropic signaling modulators that target both of these pathways providing a therapeutic strategy directed towards an integrated decrease in inflammation. This review summarizes the latest findings and understanding of the formation, signaling and anti-fibrotic effects of NO2-FA.
Collapse
Affiliation(s)
- Nicholas K H Khoo
- Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213. USA
| | - Francisco J Schopfer
- Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, 15213. USA
| |
Collapse
|
55
|
Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, Attucks OC, Franklin S, Levonen AL, Kensler TW, Dinkova-Kostova AT. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov 2019; 18:295-317. [PMID: 30610225 DOI: 10.1038/s41573-018-0008-x] [Citation(s) in RCA: 822] [Impact Index Per Article: 164.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The transcription factor NF-E2 p45-related factor 2 (NRF2; encoded by NFE2L2) and its principal negative regulator, the E3 ligase adaptor Kelch-like ECH-associated protein 1 (KEAP1), are critical in the maintenance of redox, metabolic and protein homeostasis, as well as the regulation of inflammation. Thus, NRF2 activation provides cytoprotection against numerous pathologies including chronic diseases of the lung and liver; autoimmune, neurodegenerative and metabolic disorders; and cancer initiation. One NRF2 activator has received clinical approval and several electrophilic modifiers of the cysteine-based sensor KEAP1 and inhibitors of its interaction with NRF2 are now in clinical development. However, challenges regarding target specificity, pharmacodynamic properties, efficacy and safety remain.
Collapse
Affiliation(s)
- Antonio Cuadrado
- Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Investigación Sanitaria La Paz (IdiPaz), Department of Biochemistry and Instituto de Investigaciones Biomédicas Alberto Sols UAM-CSIC, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain
- Victor Babes National Institute of Pathology, Bucharest, Romania
| | - Ana I Rojo
- Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Investigación Sanitaria La Paz (IdiPaz), Department of Biochemistry and Instituto de Investigaciones Biomédicas Alberto Sols UAM-CSIC, Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain
- Victor Babes National Institute of Pathology, Bucharest, Romania
| | - Geoffrey Wells
- UCL School of Pharmacy, University College London, London, UK
| | - John D Hayes
- Jacqui Wood Cancer Centre, Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee, Scotland, UK
| | | | | | | | | | - Anna-Liisa Levonen
- A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Thomas W Kensler
- Translational Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Albena T Dinkova-Kostova
- Jacqui Wood Cancer Centre, Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee, Scotland, UK.
- Department of Pharmacology and Molecular Sciences and Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
| |
Collapse
|
56
|
Yang RX, Fan JG. Nitro-oleic acid as a new drug candidate for non-alcoholic steatohepatitis. EBioMedicine 2019; 42:32-33. [PMID: 30948353 PMCID: PMC6491956 DOI: 10.1016/j.ebiom.2019.03.059] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Accepted: 03/19/2019] [Indexed: 02/07/2023] Open
Affiliation(s)
- Rui-Xu Yang
- Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai 200092, China
| | - Jian-Gao Fan
- Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai 200092, China.
| |
Collapse
|
57
|
Arbeeny CM, Ling H, Smith MM, O'Brien S, Wawersik S, Ledbetter SR, McAlexander A, Schopfer FJ, Willette RN, Jorkasky DK. CXA-10, a Nitrated Fatty Acid, Is Renoprotective in Deoxycorticosterone Acetate-Salt Nephropathy. J Pharmacol Exp Ther 2019; 369:503-510. [PMID: 30894457 DOI: 10.1124/jpet.118.254755] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Accepted: 01/18/2019] [Indexed: 01/29/2023] Open
Abstract
Underlying pathogenic mechanisms in chronic kidney disease (CKD) include chronic inflammation, oxidant stress, and matrix remodeling associated with dysregulated nuclear factor-κ B, nuclear factor-κ B, and SMAD signaling pathways, respectively. Important cytoprotective mechanisms activated by oxidative inflammatory conditions are mediated by nitrated fatty acids that covalently modify proteins to limit inflammation and oxidant stress. In the present study, we evaluated the effects of chronic treatment with CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) in the uninephrectomized deoxycorticosterone acetate-high-salt mouse model of CKD. After 4 weeks of treatment, CXA-10 [2.5 millligrams per kilogram (mpk), p.o.] significantly attenuated increases in plasma cholesterol, heart weight, and kidney weight observed in the model without impacting systemic arterial blood pressure. CXA-10 also reduced albuminuria, nephrinuria, glomerular hypertrophy, and glomerulosclerosis in the model. Inflammatory MCP-1 and fibrosis (collagen, fibronectin, plasminogen activator inhibitor-1, and osteopontin) renal biomarkers were significantly reduced in the CXA-10 (2.5 mpk) group. The anti-inflammatory and antifibrotic effects, as well as glomerular protection, were not observed in the enalapril-treated group. Also, CXA-10 appears to exhibit hormesis as all protective effects observed in the low-dose group were absent in the high-dose group (12.5 mpk). Taken together, these findings demonstrate that, at the appropriate dose, the nitrated fatty acid CXA-10 exhibits anti-inflammatory and antifibrotic effects in the kidney and limits renal injury in a model of CKD.
Collapse
Affiliation(s)
- Cynthia M Arbeeny
- Sanofi, Framingham (C.M.A., M.M.S., S.R.L.), Novartis (H.L., S.O.) and Scholar Rock (S.W.), Cambridge, Massachusetts; University of Pittsburgh, Pittsburgh, Pennsylvania (F.J.S) and Complexa, Inc., Berwyn, Pennsylvania (A.M., R.N.W., D.K.J.)
| | - Hong Ling
- Sanofi, Framingham (C.M.A., M.M.S., S.R.L.), Novartis (H.L., S.O.) and Scholar Rock (S.W.), Cambridge, Massachusetts; University of Pittsburgh, Pittsburgh, Pennsylvania (F.J.S) and Complexa, Inc., Berwyn, Pennsylvania (A.M., R.N.W., D.K.J.)
| | - Mandy M Smith
- Sanofi, Framingham (C.M.A., M.M.S., S.R.L.), Novartis (H.L., S.O.) and Scholar Rock (S.W.), Cambridge, Massachusetts; University of Pittsburgh, Pittsburgh, Pennsylvania (F.J.S) and Complexa, Inc., Berwyn, Pennsylvania (A.M., R.N.W., D.K.J.)
| | - Stephen O'Brien
- Sanofi, Framingham (C.M.A., M.M.S., S.R.L.), Novartis (H.L., S.O.) and Scholar Rock (S.W.), Cambridge, Massachusetts; University of Pittsburgh, Pittsburgh, Pennsylvania (F.J.S) and Complexa, Inc., Berwyn, Pennsylvania (A.M., R.N.W., D.K.J.)
| | - Stefan Wawersik
- Sanofi, Framingham (C.M.A., M.M.S., S.R.L.), Novartis (H.L., S.O.) and Scholar Rock (S.W.), Cambridge, Massachusetts; University of Pittsburgh, Pittsburgh, Pennsylvania (F.J.S) and Complexa, Inc., Berwyn, Pennsylvania (A.M., R.N.W., D.K.J.)
| | - Steven R Ledbetter
- Sanofi, Framingham (C.M.A., M.M.S., S.R.L.), Novartis (H.L., S.O.) and Scholar Rock (S.W.), Cambridge, Massachusetts; University of Pittsburgh, Pittsburgh, Pennsylvania (F.J.S) and Complexa, Inc., Berwyn, Pennsylvania (A.M., R.N.W., D.K.J.)
| | - Allen McAlexander
- Sanofi, Framingham (C.M.A., M.M.S., S.R.L.), Novartis (H.L., S.O.) and Scholar Rock (S.W.), Cambridge, Massachusetts; University of Pittsburgh, Pittsburgh, Pennsylvania (F.J.S) and Complexa, Inc., Berwyn, Pennsylvania (A.M., R.N.W., D.K.J.)
| | - Francisco J Schopfer
- Sanofi, Framingham (C.M.A., M.M.S., S.R.L.), Novartis (H.L., S.O.) and Scholar Rock (S.W.), Cambridge, Massachusetts; University of Pittsburgh, Pittsburgh, Pennsylvania (F.J.S) and Complexa, Inc., Berwyn, Pennsylvania (A.M., R.N.W., D.K.J.)
| | - Robert N Willette
- Sanofi, Framingham (C.M.A., M.M.S., S.R.L.), Novartis (H.L., S.O.) and Scholar Rock (S.W.), Cambridge, Massachusetts; University of Pittsburgh, Pittsburgh, Pennsylvania (F.J.S) and Complexa, Inc., Berwyn, Pennsylvania (A.M., R.N.W., D.K.J.)
| | - Diane K Jorkasky
- Sanofi, Framingham (C.M.A., M.M.S., S.R.L.), Novartis (H.L., S.O.) and Scholar Rock (S.W.), Cambridge, Massachusetts; University of Pittsburgh, Pittsburgh, Pennsylvania (F.J.S) and Complexa, Inc., Berwyn, Pennsylvania (A.M., R.N.W., D.K.J.)
| |
Collapse
|
58
|
Rom O, Xu G, Guo Y, Zhu Y, Wang H, Zhang J, Fan Y, Liang W, Lu H, Liu Y, Aviram M, Liu Z, Kim S, Liu W, Wang X, Chen YE, Villacorta L. Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice. EBioMedicine 2019; 41:62-72. [PMID: 30772307 PMCID: PMC6444056 DOI: 10.1016/j.ebiom.2019.02.019] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Revised: 02/07/2019] [Accepted: 02/07/2019] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are reaching global epidemic proportions. Lack of non-invasive diagnostic tools and effective therapies constitute two of the major hurdles for a bona fide treatment and a reversal of NASH progression and/or regression of the disease. Nitro-oleic acid (OA-NO2) has been proven effective in multiple experimental models of inflammation and fibrosis. Thus, the potential benefit of in vivo administration of OA-NO2 to treat advanced NAFLD was tested herein in a model of long-term NASH diet-induced liver damage. METHODS Non-invasive imaging (e.g. photoacustic-ultrasound (PA-US)) was pursued to establish advanced experimental model of NASH in mice in which both steatosis and fibrosis were diagnosed prior experimental therapy with OA-NO2. Experimental controls included equimolar amounts of the non-nitrated oleic acid (OA). CLAMS and NMR-based analysis was used for energy metabolism. FINDINGS CLAMS and NMR-based analysis demonstrates that OA-NO2 improves body composition and energy metabolism and inhibits hepatic triglyceride (TG) accumulation. Photoacoustic-ultrasound imaging revealed a robust inhibition of liver steatosis and fibrosis by OA-NO2. RNA-sequencing analysis uncovered inflammation and fibrosis as major pathways suppressed by OA-NO2 administration, as well as regulation of lipogenesis and lipolysis pathways, with a robust inhibition of SREBP1 proteolytic activation and subsequent lipogenesis gene expression by OA-NO2. These results were further supported by histological analysis and quantification of lipid accumulation, lobular inflammation (F4/80 staining) and fibrosis (collagen deposition, αSMA staining) as well as established parameters of liver damage (ALT). In vitro studies indicate that OA-NO2 inhibits TG biosynthesis and accumulation in hepatocytes and inhibits fibrogenesis in human stellate cells. INTERPRETATION OA-NO2 improve steatohepatitis and fibrosis and may constitute an effective therapeutic approach against advanced NAFLD that warrants further clinical evaluation.
Collapse
Affiliation(s)
- Oren Rom
- Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
| | - Guan Xu
- Department of Radiology, Michigan Medicine, Ann Arbor, MI, USA
| | - Yanhong Guo
- Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
| | - Yunhao Zhu
- Department of Radiology, Michigan Medicine, Ann Arbor, MI, USA
| | - Huilun Wang
- Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
| | - Jifeng Zhang
- Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
| | - Yanbo Fan
- Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
| | - Wenying Liang
- Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
| | - Haocheng Lu
- Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
| | - Yuhao Liu
- Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
| | - Michael Aviram
- The Lipid Research Laboratory, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
| | - Zhipeng Liu
- Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana, USA
| | - Seongho Kim
- Biostatistics Core, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
| | - Wanqing Liu
- Department of Pharmaceutical Sciences and Pharmacology, Wayne State University, Detroit, MI, USA
| | - Xueding Wang
- Department of Radiology, Michigan Medicine, Ann Arbor, MI, USA
| | - Y Eugene Chen
- Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
| | - Luis Villacorta
- Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA.
| |
Collapse
|
59
|
Melo T, Montero-Bullón JF, Domingues P, Domingues MR. Discovery of bioactive nitrated lipids and nitro-lipid-protein adducts using mass spectrometry-based approaches. Redox Biol 2019; 23:101106. [PMID: 30718106 PMCID: PMC6859590 DOI: 10.1016/j.redox.2019.101106] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Revised: 01/08/2019] [Accepted: 01/10/2019] [Indexed: 01/01/2023] Open
Abstract
Nitro-fatty acids (NO2-FA) undergo reversible Michael adduction reactions with cysteine and histidine residues leading to the post-translational modification (PTM) of proteins. This electrophilic character of NO2-FA is strictly related to their biological roles. The NO2-FA-induced PTM of signaling proteins can lead to modifications in protein structure, function, and subcellular localization. The nitro lipid-protein adducts trigger a series of downstream signaling events that culminates with anti-inflammatory, anti-hypertensive, and cytoprotective effects mediated by NO2-FA. These lipoxidation adducts have been detected and characterized both in model systems and in biological samples by using mass spectrometry (MS)-based approaches. These MS approaches allow to unequivocally identify the adduct together with the targeted residue of modification. The identification of the modified proteins allows inferring on the possible impact of the NO2-FA-induced modification. This review will focus on MS-based approaches as valuable tools to identify NO2-FA-protein adducts and to unveil the biological effect of this lipoxidation adducts.
Collapse
Affiliation(s)
- Tânia Melo
- Centro de Espectrometria de Massa, Departamento de Química & QOPNA, Universidade de Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; Departamento de Química & CESAM & ECOMARE, Universidade de Aveiro, 3810-193 Aveiro, Portugal.
| | - Javier-Fernando Montero-Bullón
- Centro de Espectrometria de Massa, Departamento de Química & QOPNA, Universidade de Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.
| | - Pedro Domingues
- Centro de Espectrometria de Massa, Departamento de Química & QOPNA, Universidade de Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.
| | - M Rosário Domingues
- Centro de Espectrometria de Massa, Departamento de Química & QOPNA, Universidade de Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; Departamento de Química & CESAM & ECOMARE, Universidade de Aveiro, 3810-193 Aveiro, Portugal.
| |
Collapse
|
60
|
Kelley EE. Diminishing Inflammation by Reducing Oxidant Generation: Nitrated Fatty Acid-Mediated Inactivation of Xanthine Oxidoreductase. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2019; 1127:59-65. [PMID: 31140171 DOI: 10.1007/978-3-030-11488-6_4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Inhibition of xanthine oxidoreductase (XOR) has proven beneficial in a plethora of inflammatory disease processes due to a net reduction in pro-inflammatory oxidants and secondary nitrating species. Electrophilic nitrated fatty acid derivatives, such as nitro-oleic acid (OA-NO2) are also noted to display a broad spectrum of anti-inflammatory effects via interaction with critical signaling pathways. An alternative process in which nitrated fatty acids may extend anti-inflammatory actions is via inactivation of XOR, a process that is more effective than allo/oxypurinol-mediated inhibition. Herein, we describe the molecular aspects of nitrated fatty acid-associated inactivation of XOR, identify specificity via structure function relationships and discuss XOR as a crucial component of the anti-inflammatory portfolio of nitrated fatty acids.
Collapse
Affiliation(s)
- Eric E Kelley
- Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV, USA.
| |
Collapse
|